Dr. Hoff on Continued Angiogenesis Suppression Following Progression on Bevacizumab in mCRC

Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses continued angiogenesis suppression following progression on bevacizumab in metastatic colorectal cancer. This study, which analyzes the consistency of effect of ziv-aflibercept in the bevacizumab pre-treated subgroup of patients in the VELOUR trial stratified by first-line progression greater than or equal to 9 months versus less than 9 months, was presented at the 2014 ASCO Annual Meeting. For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/